PMH21 COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
Abstract
Authors
H Ascher-Svanum NM Furiak RW Klein W Montgomery LJ Smolen AH Lawson RR Conley